X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pfizer Fact Sheet, Pfizer Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pfizer Fact Sheet   (PFIZ)

Here is the latest financial fact sheet of Pfizer. For more details, see the Pfizer quarterly results and Pfizer share price and chart. For a sector overview, read our pharmaceuticals sector report.

PFIZER Price History

Price Rs 2,285.1
Mkt Cap Rs m 104,541
Vol '000 1.1
P/E X 31.0
P/CF X 30.2
EPS (TTM) Rs 73.6
% ch % -0.6
No. of shares m 45.75
% ch week % -1.6
% ch 1-mth % 6.6
% ch 12-mth % 31.0
52 week H/L Rs 2,365.0/1,625.0
(As on Feb 21, 2018 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

PFIZER Financials

No. of Mths
Year Ending
12
Mar-12
12
Mar-13
12
Mar-14
12
Mar-15
12
Mar-16
5-Yr Chart
Click to enlarge
PFIZER EQUITY SHARE DATA
High Rs1,6361,4101,7792,3252,724 
Low Rs1,0729999851,1751,611 
Sales per share (Unadj.) Rs366.4351.5372.6405.1440.9 
Earnings per share (Unadj.) Rs61.9168.674.015.348.7 
Diluted earnings per shareRs40.4110.048.315.348.7 
Cash flow per share (Unadj.) Rs65.1171.376.743.975.8 
Dividends per share (Unadj.) Rs12.5032.50360.0012.5015.00 
Adj. dividends per shareRs8.1521.20234.8112.5015.00 
Dividend yield (eoy) %0.92.726.00.70.7 
Book value per share (Unadj.) Rs437.2567.8220.6431.3462.9 
Adj. book value per shareRs285.2370.4143.9431.3462.9 
Shares outstanding (eoy) m29.8429.8429.8445.7545.75 
Bonus/Rights/Conversions  ---A- 
Price / Sales ratio x3.73.43.74.34.9 
Avg P/E ratio x21.97.118.7114.744.5 
P/CF ratio (eoy) x20.87.018.039.928.6 
Price / Book Value ratio x3.12.16.34.14.7 
Dividend payout %20.219.3486.481.930.8 
Avg Mkt Cap Rs m40,40335,93641,23980,06399,163 
No. of employees `0003.22.82.4NA2.9 
Total wages/salary Rs m1,9282,1111,9182,3642,758 
Avg. sales/employee Rs Th3,469.73,752.64,600.0NM6,981.7 
Avg. wages/employee Rs Th611.9755.3793.4NM954.5 
Avg. net profit/employee Rs Th585.91,800.4913.8NM771.1 
PFIZER INCOME DATA
Net Sales Rs m10,93310,48811,11818,53320,170 
Other income Rs m9271,0521,094674857 
Total revenues Rs m11,86011,54112,21219,20721,028 
Gross profit Rs m1,9531,8272,3853,8304,310 
Depreciation Rs m9680801,3111,239 
Interest Rs m62485 
Profit before tax Rs m2,7792,7973,3963,1853,923 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m-44,1410-1,11099 
Tax Rs m9291,9061,1871,3771,794 
Profit after tax Rs m1,8465,0322,2096982,228 
Gross profit margin %17.917.421.520.721.4 
Effective tax rate %33.468.135.043.245.7 
Net profit margin %16.948.019.93.811.0 
PFIZER BALANCE SHEET DATA
Current assets Rs m13,30818,0446,86012,52016,299 
Current liabilities Rs m2,5103,5093,0346,0857,594 
Net working cap to sales %98.8138.634.434.743.2 
Current ratio x5.35.12.32.12.1 
Inventory Days Days6157507665 
Debtors Days Days4749573226 
Net fixed assets Rs m3192592329,5698,622 
Share capital Rs m298298298458458 
"Free" reserves Rs m12,74916,6466,28619,27320,722 
Net worth Rs m13,04716,9446,58419,73021,180 
Long term debt Rs m0002525 
Total assets Rs m15,81620,5959,76726,13729,137 
Interest coverage x472.01,166.2944.3414.6755.5 
Debt to equity ratio x00000 
Sales to assets ratio x0.70.51.10.70.7 
Return on assets %11.724.422.72.77.7 
Return on equity %14.129.733.53.510.5 
Return on capital %21.341.051.610.519.0 
Exports to sales %0.20.100.10.1 
Imports to sales %9.48.99.423.117.5 
Exports (fob) Rs m17125912 
Imports (cif) Rs m1,0309321,0504,2743,526 
Fx inflow Rs m2211558311752 
Fx outflow Rs m1,1601,2659,4314,383140 
Net fx Rs m-939-1,110-9,348-4,266-88 
PFIZER CASH FLOW
From Operations Rs m 245 -160 1,325 1,135 3,436 
From Investments Rs m 2,775 6,259 1,027 -888 -6,991 
From Financial Activity Rs m -141 -432 -13,602 -14 -619 
Net Cashflow Rs m 2,879 5,667 -11,251 233 -4,174 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 0.0%
Foreign collaborators 63.9%
Indian inst/Mut Fund 7.5%
FIIs 4.9%
ADR/GDR 0.0%
Free float 23.7%
Shareholders 85,207
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Pfizer Centre, Patel Estate, S. V. Road, Jogeshwari (W), Mumbai - 400 102
E-MAIL prajeet.nair@pfizer.com WEB www.pfizerindia.com
TELEPHONE (022) 6693 2000 FAX (022) 2678 4569
SECTOR PHARMACEUTICALS GROUP M N C
TR AGENT Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR B S R & Co. LLP
CHM: R. A. Shah COMP SEC: Prajeet Nair YEAR OF INC: 1950 BSE CODE: 500680 FV (Rs): 10 DIV YIELD (%): 0.7

More Pharmaceuticals Company Fact Sheets:   J.B.CHEMICALS  INDOCO REMEDIES  CIPLA  ORCHID PHARMA LTD  GSK PHARMA  

Compare PFIZER With:   J.B.CHEMICALS  INDOCO REMEDIES  CIPLA  ORCHID PHARMA LTD  GSK PHARMA  

Compare PFIZER With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Views on news

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK PFIZER

MORE ON PFIZER

PFIZER - ACTAVIS COMPARISON

COMPARE PFIZER WITH

MARKET STATS